Comparing the Neurotoxicity of the Cancer Drugs Cisplatin and Oxaliplatin

Dan Barkmeier  
*Illinois Wesleyan University*

Anthony Windebank, Faculty Advisor  
*Illinois Wesleyan University*

Follow this and additional works at: [https://digitalcommons.iwu.edu/jwprc/2004/posters/4](https://digitalcommons.iwu.edu/jwprc/2004/posters/4)

[https://digitalcommons.iwu.edu/jwprc/2004/posters/4](https://digitalcommons.iwu.edu/jwprc/2004/posters/4)

This is protected by copyright and/or related rights. It has been brought to you by Digital Commons @ IWU with permission from the rights-holder(s). You are free to use this material in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself. This material has been accepted for inclusion by faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.  
©Copyright is owned by the author of this document.
COMPARING THE NEUROTOXICITY OF THE CANCER DRUGS CISPLATIN AND OXALIPLATIN

Dan Barkmeier and Anthony Windebank*
Department of Biology, Illinois Wesleyan University
Department of Molecular Neuroscience, Mayo Clinic

Cisplatin is a platinum-based drug that has been used to successfully treat cancer since the 1970s, especially testicular and ovarian cancer. Cisplatin acts by binding to DNA and interfering with DNA replication, which most significantly affects rapidly dividing cells like cancer. However, the dosage that can be given to patients is limited by cisplatin’s damage to the dorsal root ganglia, which are responsible for somatic sensory. A variety of similar platinum drugs have therefore been tested for less damaging neurotoxicity profiles. One of these compounds, oxaliplatin, was recently approved for treatment of colorectal cancer. Relatively little is known about its exact mechanism of action and neurotoxicity though. The goal of this project was to compare the neurotoxicity of cisplatin versus oxaliplatin and to further characterize the mechanism of oxaliplatin action. Results are not definite yet, but oxaliplatin causes apoptosis just like cisplatin, seems to cause less neuron cell death at equimolar concentrations, and both binds to and releases from neuron cell DNA more slowly than cisplatin.